Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL23149384

Fc1cc(C(F)(F)F)ccc1COC1C[C@H]2CC[C@@H](C1)N2.O=C(O)C(F)(F)F

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 5/20 0.44
SLC6A2 P23975 4/20 0.44
SLC6A3 Q01959 3/20 0.44
IDO1 P14902 1/20 0.43
NAAA Q02083 1/20 0.43
FFAR1 O14842 1/20 0.39
LIPG Q9Y5X9 3/20 0.38
ENPP2 Q13822 3/20 0.38
ATXN2 Q99700 3/20 0.38
LTC4S Q16873 1/20 0.37
LPL P06858 2/20 0.36
LIPC P11150 2/20 0.36
FFAR4 Q5NUL3 1/20 0.36
CHRNA7 P36544 1/20 0.36
MGLL Q99685 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL23149380 1.00 SLC6A4 (0.44) SLC6A4SLC6A2SLC6A3IDO1NAAA
SCHEMBL23105361 0.92 SLC6A4 (0.50) SLC6A4SLC6A2SLC6A3IDO1NAAA
SCHEMBL30700758 0.92 SLC6A4 (0.50) SLC6A4SLC6A2SLC6A3IDO1NAAA
SCHEMBL23105360 0.92 SLC6A4 (0.50) SLC6A4SLC6A2SLC6A3IDO1NAAA
Trifluoroacetic Acid SCHEMBL26649036 0.90 NAAA (0.41) SLC6A4SLC6A2SLC6A3IDO1NAAA
Trifluoroacetic Acid SCHEMBL29569486 0.90 NAAA (0.41) SLC6A4SLC6A2SLC6A3IDO1NAAA
Trifluoroacetic Acid SCHEMBL23091803 0.84 NAAA (0.43) SLC6A4SLC6A2SLC6A3IDO1NAAA
Trifluoroacetic Acid SCHEMBL23152297 0.84 IDO1 (0.47) SLC6A4SLC6A2SLC6A3IDO1NAAA
SCHEMBL23105362 0.81 IDO1 (0.47) SLC6A4SLC6A2SLC6A3IDO1NAAA
SCHEMBL31308833 0.81 IDO1 (0.49) SLC6A4SLC6A2SLC6A3IDO1NAAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220275005-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2022-09-01 US disclosed
EP-4028401-A1 4,4A,5,7,8,8A-HEXAPYRIDO[4,3-B][1,4]OXAZIN-3-ONE COMPOUNDS AS MAGL INHIBITORS F. Hoffmann-La Roche AG (CH) 2022-07-20 EP disclosed
CN-114364682-A Compound 4,4A,5,7,8, 8A-hexapyrido [4,3-B ] [1,4] oxazin-3-one as MAGL inhibitor 豪夫迈·罗氏有限公司 2022-04-15 CN disclosed
US-20210094971-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2021-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210094971-A1 HETEROCYCLIC COMPOUNDS CYP1B1, CYP4B1, CYP4X1 SLC6A4 4287/4885SLC6A2 4539/4885SLC6A3 4556/4885
US-20220275005-A1 HETEROCYCLIC COMPOUNDS CYP1B1, CYP4B1, CYP4X1 SLC6A4 4287/4885SLC6A2 4539/4885SLC6A3 4556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.